Therapeutic and legal aspects of psilocybin in cancer-related depression - Małgorzata Wierzbicka; Renata Kopczyk; Aleksandra Gerlach; Joanna Rymaszewska (Frontiers in Psychiatry, 2025)

Interventions to support spirituality among adults with cancer: a scoping review. - Miller M; Meyers M; Krainak K; Lewis SP. (2025)

Psychedelics as treatment of alcohol use disorders: insights from preclinical models and comparison of the different psychedelics psilocybin, LSD and ketamine - Mickaël Naassïla (Neuroscience, 2025)

519. PSILOCYBIN ASSISTED PSYCHOTHERAPY FOR OBSESSIVE COMPULSIVE DISORDER, BODY DYSMORPHIC DISORDER, AND ANOREXIA NERVOSA: STUDY PROTOCOL (2025)

631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS (2025)

317. PSILOCYBIN DOES NOT INDUCE CONDITIONED PLACE PREFERENCE, BUT MODIFIES BEHAVIORAL PATTERNS IN SPRAGUE-DAWLEY RATS (2025)

164. PSILOCYBIN DURING THE POSTPARTUM PERIOD INDUCES LONG-LASTING ADVERSE EFFECTS IN BOTH MOTHERS AND OFFSPRING (2025)

620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER (2025)

426. THE MGLUR2/3 ANTAGONIST ENHANCES THE BEHAVIORAL AND CELLULAR ANTIDEPRESSANT-LIKE EFFECTS OF PSILOCYBIN AND SCOPOLAMINE (2025)

694. INVESTIGATING THE POTENTIAL OF PSILOCYBIN FOR COMPULSIVE EATING IN A RAT MODEL OF BINGE EATING (2025)

363. DIFFERENTIAL EFFECTS OF PSILOCYBIN AND LISURIDE ON SEROTONIN AND DOPAMINE NEURONAL ACTIVITY AND BEHAVIOR (2025)

229. PSILOCYBIN WITH PSYCHOTHERAPEUTIC SUPPORT FOR TREATMENT-RESISTANT DEPRESSION: A PILOT CLINICAL TRIAL (2025)

205. SYNERGISTIC BEHAVIORAL AND NEUROPLASTIC EFFECTS OF PSILOCYBIN-NMDAR MODULATOR ADMINISTRATION (2025)

564. TOWARD AN UNDERSTANDING OF THE THERAPEUTICALLY RELEVANT MECHANISMS OF PSILOCYBIN FOR ANOREXIA NERVOSA (2025)

476. ACUTE AND CHRONIC PSILOCYBIN IN MOUSE MODELS OF PSYCHIATRIC DISORDERS (2025)

597. ARE SIDE EFFECTS NECESSARY FOR ANTIDEPRESSIVE TREATMENT: THE PSILOCYBIN EXPERIENCE (2025)

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers. - Ley L; Liechti ME; Becker AM; Straumann I; Klaiber A; Holze F; Vogt SB; Arikci D; Schmid Y (Psychopharmacology, 2025)

Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review. - Sulstarova A; Scheuerlein L; Monari S; Seragnoli F; Gabriel T; Preller K; Böge K; Sentissi O; Kaiser S; Solmi M; Kirschner M; Sabé M (Asian journal of psychiatry, 2025)

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms. - Adebo M; Bonnet M; Laouej O; Defaix C; McGowan JC; Butlen-Ducuing F; David DJ; Poupon E; Tritschler L; Gardier AM. (2025)

Correction to "Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis". (2025)

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. - Liechti ME; Gasser P; Aicher HD; Mueller F; Hawrot T; Schmid Y. (2025)

Psilocybin Prolongs the Neurovascular Coupling Response in Mouse Visual Cortex - Zirkel RT; Isaacson M; Liao C; Yi M; Yamaguchi K; Rivera D; Kuceyeski A; Nishimura N; Kwan AC; Schaffer CB. (bioRxiv, 2025)

Psilocybin-assisted treatment of depression - Barbara Anna Zapalska; Antonina Teresa Witkowska; Anna Cukrowska; Artur Galus (Medical Science, 2025)

Meditation, Psychedelics, and Brain Connectivity: A Randomised Controlled Resting-State fMRI Study of N,N-Dimethyltryptamine and Harmine in a Meditation Retreat - Egger K; Meling D; Polat F; Seifritz E; Avram M; Scheidegger M. (medRxiv, 2025)

Meaning-Centered Psychotherapy for Psilocybin-Assisted Therapy Among Patients with Advanced Cancer and Depression: Rationale and Preliminary Evaluation of MCP-PSIL. - Rosa WE; Napolitano S; McAndrew N; Jenkins B; Lichtenthal WG; Applebaum AJ; Breitbart W; Agrawal M. (2025)

Electrophysiological effects of psilocybin co-administered with midazolam - Sutherland MH; Nicholas CR; Lennertz RC; Wenthur CJ; Krause BM; Sauder CJ; Riedner BA; Smith RF; Hutson PR; Raison CL; Banks MI. (bioRxiv, 2025)

Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials. - Bevione F; Lacidogna MC; Lavalle R; Abbate Daga G; Preti A. (2025)

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial - Johns Hopkins University (ClinicalTrials.gov, 2025)

Modulation of Serotonin Pathways Using Psilocybin in Adults With and Without Autism Spectrum Disorder (ASD) - King's College London (ClinicalTrials.gov, 2025)

Global Increases in Brain Glucose Metabolism Following Acute N,N-Dimethyltryptamine and Harmine Administration in Healthy Volunteers: An [¹⁸F]FDG-PET Study - Egger K; Bozsak R; Aicher H; Sari H; Poetzsch S; Rominger A; Martin-Soelch C; Dornbierer D; Quednow B; Scheidegger M; Cumming P. (Research Square, 2025)

Molecular Pathways Potentially Involved in Hallucinatory Experiences During Sleep Paralysis: The Emerging Role of β-Arrestin-2. - Rudy LM; Godlewski MM. (2025)

An overview of psilocybin, LSD, MDMA, and ketamine in revitalizing psychedelic-assisted therapy: Insights, limitations and future directions. - Askariyan K; Joghataei MT; Dehghan S; Nohesara S; Riahi Pour L; Mohammadi MH; Ahmadirad N. (2025)

Mechanistic Studies of Psilocybin in Headache Disorders - Yale University (ClinicalTrials.gov, 2025)

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial - Amandine Luquiens; Dahbia Belahda; Carine Graux; Noe Igounenc; Chris Serrand; Paul A. Rochefort; Thibault Mura; Felix Sergent (Addiction, 2025)

The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC) - Emory University (ClinicalTrials.gov, 2025)

Avoiding Stigma and Sensationalism in Therapeutic Psilocybin Communications: Considerations for Reaching Older Patients - C. Gillespie; Jesse M. Bering (American Journal of Geriatric Psychiatry, 2025)

“I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke - Patricia A. Cioe; Garrett S Stang; Danish Azam; Sarah Dugal (Addiction Science & Clinical Practice, 2025)

Psilocybin as a psychophysical adaptogen in chronic pain rehabilitation - Nicholas P. Cherup; Patrick H. Finan (Journal of Pain, 2025)

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality - The University of Texas Health Science Center; Houston (ClinicalTrials.gov, 2025)

Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder - Urban MM; Zillich L; Rieser NM; Herdener M; Vollenweider FX; Spanagel R; Preller KH; Meinhardt MW. (bioRxiv, 2025)

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics. - Jain MK; Gumpper RH; Slocum ST; Schmitz GP; Madsen JS; Tummino TA; Suomivuori CM; Huang XP; Shub L; DiBerto JF; Kim K; DeLeon C; et al. (2025)

Mapping psilocybin therapy: A systematic review of therapeutic frameworks, adaptations, and standardization across contemporary clinical trials. - Kittur ME; Burgos M LA; Jones BDM; Blumberger DM; Mulsant BH; Rosenblat JD; Husain MI. (2025)

Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns - Ashutosh Bhave (Journal of Public Policy & Marketing, 2025)

Stronger visual surround suppression under psilocybin: A psychophysical and EEG pilot study - Michael-Paul Schallmo; Sophia Jungers; Ranji Varghese; Kathryn R. Cullen; Michael D. Evans; Jessica L. Nielson; Link Swanson (Journal of Vision, 2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases - Heller NH; Barrett FS; Buchborn T; Collerton D; Dupuis D; Halberstadt AL; Jardri R; Noorani TN; Preller KH; Taylor J; Waters F; Winston B; et al. (PsyArXiv, 2025)

Biochemical Insights into Diverse Psilocybe Mushrooms and Their Metabolites as Sources of Neuroactive Agents: A Review. - Sudhakaran G; Chakraborty S; Kumar A; Bharti SAK; Csaba V; Valan Arasu M; Namasivayam SKR; Arockiaraj J. (2025)

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases (PsyArXiv, 2025)

Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury. - Plummer Z; Allen J; Brand J; Mayo LM; Shultz SR; Christie BR. (2025)

Equitable access to psilocybin-assisted psychotherapy in New Zealand. - Lacey C. (2025)

Females in Psychedelic Research: A Perspective for Advancing Research and Practice. - Cohen ZZ; Blest-Hopley G (ACS pharmacology & translational science, 2025)

A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction. - Glenn DL; Choi SH; Zimmerman RS. (2025)

Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms - Taynah Pereira Galdino; Lucas Cordeiro de Oliveira; Mateus Araújo da Luz; R.C.A. Barbosa; M. Torres; Kátia Sivieri; Paula A. Fernandes; Márcio Luiz dos Santos; Antônio Gilson Barbosa de Lima; Suédina Maria de Lima Silva; Marcus Vinícius Lia Fook (ACS Omega, 2025)

Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action. - Miller EA; Capone C; Eaton E; Swift RM; Haass-Koffler CL. (2025)

Treatment with LSD and psilocybin at the department of psychiatry at Frederiksberg Hospital in Denmark from 1960 to 1973: an analysis of 324 cases - Jens Larsen; Pernille Kølbæk; Søren Dinesen Østergaard (Nordic Journal of Psychiatry, 2025)

The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin - Miyuan Zhang (21677016); Haojiang Zhai (21677019); Longwei Yang (21677022); Haohong Li (5164970); Xiaohui Wang (19899) (Figshare, 2025)

Psilocybin treatment extends cellular lifespan and improves survival of aged mice - Kosuke Kato; Jennifer Kleinhenz; Yoon-Joo Shin; Cristian Coarfa; Ali John Zarrabi; Louise Hecker (npj Aging, 2025)

The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin - Miyuan Zhang; Haiyan Zhai; Longwei Yang; Haohong Li; Xiaohui Wang (ACS Pharmacology & Translational Science, 2025)

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India. - Joga R; Yerram S; Patnam JD; Choudhary KK; Varpe P; Raghuvanshi RS; Srivastava S. (2025)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression - Szigeti B. (PsyArXiv, 2025)

An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression (PsyArXiv, 2025)

Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models - Gregory NS; Girard TE; Ram A; Casey AB; Malenka RC; Tawfik VL; Heifets BD. (bioRxiv, 2025)

The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine. - Park D; Lee G; Lee WG; Kim B; Lee Y; Kim JW. (2025)

Explore the effect of psilocybin on depression and anxiety - Yutong Song (Arts Culture and Language, 2025)

Effects of Psilocin and Psilocybin on Human 5-HT4 Serotonin and H2 Histamine Receptors in Perfused Hearts of Transgenic Mice - Pauline Braekow; Joachim Neumann; Uwe Kirchhefer; Ulrich Gergs (Pharmaceuticals, 2025)

Accurate and Interpretable Prediction of Antidepressant Treatment Response from Receptor-informed Neuroimaging - Tolle HM; Luppi AI; Lawn T; Roseman L; Nutt D; Carhart-Harris RL; Mediano PAM. (bioRxiv, 2025)

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study - Luca Pellegrini; Naomi Fineberg; Sorcha O'Connor; Ana Maria Frota Lisbôa Pereira de Souza; Kate Godfrey; Sara Reed; Joseph Peill; Mairead Healy; Cyrus Rohani-Shukla; Hakjun Lee; Robin Carhart-Harris; Trevor W. Robbins; et al. (Comprehensive Psychiatry, 2025)

Psilocybin bei schwerer behandlungsresistenter Depression (Fortschritte der Neurologie · Psychiatrie, 2025)

Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report - David W. Lawrence; Alex P. Di Battista; Michael G. Hutchison (Psychoactives, 2025)

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties. - Atiq MA; Baker MR; Voort JLV; Vargas MV; Choi DS (Psychopharmacology, 2025)

Exploring serotonergic psychedelics as a treatment for personality disorders. - Carrithers BM; Roberts DE; Weiss BM; King JD; Carhart-Harris RL; Gordon AR; Pagni BA; Moreau M; Ross S; Zeifman RJ (Neuropharmacology, 2025)

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises. - Harding R; Singer N; Wall MB; Hendler T; Erritzoe D; Nutt D; Carhart-Harris R; Roseman L. (2025)

What fMRI studies say about the nature of the psychedelic effect: a scoping review. - Beneš M; Páleníček T; Horáček J. (2025)

Efficient Acyloxymethylation of Psilocin and Other Tryptamines Yielding ACOM Prodrugs for Psychedelic-Assisted Therapy - Judith Stirn; Christian D. Klein (Archiv der Pharmazie, 2025)

Psychedelic drugs for the treatment of substance use disorders. - Sofuoglu M; De Aquino JP; MacLean RR (Expert review of clinical pharmacology, 2025)

Chemical Composition and Biological Activities of Psilocybe Mushrooms: Gaps and Perspectives. - Luz MA; Guedes HVS; Bisneto ABM; Jesus RA; Galdino TP; Oliveira LC; Afonso VI; Fook MVL; Lima AGB; Silva SML; Torres MCM. (2025)

Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis. - Hieronymus F; López E; Werin Sjögren H; Lundberg J. (2025)

Synthesis of Psilocin, Psilocybin and 5-MeO-DMT Succinate, All Labelled With Carbon-14 at the Indole 2-Position - Rodney D. Brown; Niall M. Hamilton; Connor Mallon; James Stevenson; Michael T. Faley; Robert B. Kargbo; Alexander M. Sherwood; Balasubramaniam Upeandran (Journal of Labelled Compounds and Radiopharmaceuticals, 2025)

Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances - Samuel E Christen; Elias Bekka; Yasmin Schmid; Neal L. Benowitz; Evangelia Liakoni (Swiss Medical Weekly, 2025)

Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats - Hynek Danda; Kristýna Mazochová; Klára Šíchová; Vladimír Mazoch; Lucie Olejníková Ladislavová; Kateřina Syrová; Bronislav Jurásek; Petra Cihlářová; Radek Jurok; Tomáš Páleníček; Martin Kuchař (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2025)

Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry - Islam S; Liden T; Goff R; Schug KA. (2025)

Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review. - Ciszowski K; Ziaja A; Niedzielska-Andres E; Pomierny-Chamioło L. (2025)

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression - Ryan M. Brudner; Erica Kaczmarek; Marc G. Blainey; Christian Schulz; Shakila Meshkat; Zoe Doyle; Orly Lipsitz; Hilary Offman; Rickinder Sethi; Geneva Weiglein; Roger S. McIntyre; Joshua D. Rosenblat (Journal of Psychopharmacology, 2025)

Prolonged hallucinogenic effects following Psilocybe cubensis ingestion: Case report - Rodrigo A. Petter; María D. Montero; Cinthia D. Gigliotti (The poison., 2025)

Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis. - Schuman HDM; Savard C; Mina R; Barkova S; Conradi HSW; Deleemans JM; Carlson LE. (2025)

Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease - Nayiri Barton (Global Journal of Medical Research, 2025)

A Scoping Review of Research in Naturalistic Studies with Psychedelics. - Carvalho LC; Encantado J; Kettner H; Timmermann C; Veiga D; Teixeira PJ. (2025)

Visual Surround Suppression and Perceptual Expectation Under Psilocybin - University of Minnesota (ClinicalTrials.gov, 2025)

Psilocybin Modulates TPJ Effective Connectivity during Out-of-Body Experiences - Stoliker D; Bernasconi F; Blanke O; Razi A. (medRxiv, 2025)

The Clinical Applications of Psilocybin Therapies and Post-COVID Syndrome: A Comprehensive Narrative Review. - Mathew A; Dongre R; Kim SH; Turner J; Mathew A; Cherryholmes E; Mehrinfar M; Kamprath S. (2025)

Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows. - Vinarcsik L; Smoller C; Grossberg G. (2025)

The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping Review - Daroui D; Mastrostefano A; Davini F; Giuseppe G; Terracina S. (Preprints.org, 2025)

Molecular, haemodynamic and functional effects of LSD in the human brain - McCulloch DE; Larsen K; Johansen A; Reveles Jensen KH; Nykjaer CH; Holze F; Falck N; Neufeld VAB; Steenstrup E; Skov-Andersen PM; Spangaard A; Geisler M; et al. (medRxiv, 2025)

Correction: Psilocybin's acute and persistent brain effects: a precision imaging drug trials. - Subramanian S; Reneau TR; Perry D; Chacko R; Laumann TO; Flavin K; Horan C; Schweiger J; Metcalf N; Lenze EJ; Snyder AZ; Dosenbach NUF; et al. (Scientific data, 2025)

“Diversity makes the richness of humanity”: The emergence and persistence of mental imagery after self-reported psilocybin truffles intake in an autistic woman with “blind imagination” (aphantasia): A33-month retrospective case report - Kevin Rebecchi (Journal of Psychedelic Studies, 2025)

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses - Ying Zhang; Lei Yang; Qiuyu Zhang; Chao Li; Fuqiang Mao; Chuanjun Zhuo (Translational Psychiatry, 2025)

Long-term benefits of single-dose psilocybin in depressed patients with cancer - Manish Agrawal; Kim Roddy; Betsy Jenkins; Celia Leeks; Ezekiel Emanuel (Cancer, 2025)

Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress - Ines Erkizia-Santamaría; Igor Horrillo; Nerea Martínez-Álvarez; Daniel Pérez-Martínez; Guadalupe Rivero; Amaia M. Erdozain; J. Javier Meana; Jorge E. Ortega (Translational Psychiatry, 2025)

Escitalopram/psilocybin (Reactions Weekly, 2025)

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder - COMPASS Pathways (ClinicalTrials.gov, 2025)

Mycelium Growth and Development of Psilocybe spp. Mother Cultures on Agar-Based Media - Marco Pepe; Mohsen Hesami; Livia Fleishmann; Tom Hsiang; Andrew Maxwell Phineas Jones (Journal of Fungi, 2025)

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2025)

Is there mush-room to improve the environmental sustainability of psilocybin production? - Luke Lanham; Alistair R. McTaggart; James R. Falconer (Journal of CO2 Utilization, 2025)

Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder - Agin-Liebes G; Petridis P; Zeifman R; Link M; Cordova MJ; Bogenschutz M. (PsyArXiv, 2025)

Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults - University of California; San Francisco (ClinicalTrials.gov, 2025)

Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder (PsyArXiv, 2025)

Psilocybin and hallucinogenic mushrooms - ERRATUM. - Fradet M; Kelly CM; Donnelly AJ; Suppes T. (2025)

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study - Sara Ellis; Catherine Bostian; Anna J. Donnelly; Wendy Feng; Katherine Eisen; Melanie Lean; Elizabeth Conlan; Michael J. Ostacher; Scott T. Aaronson; Trisha Suppes (Journal of Affective Disorders, 2025)

Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework. - Modlin NL; Williamson V; Maggio C; Stubley J; Kirlic N; Cleare A; Rucker J. (2025)

"Wood-lover paralysis": Describing a toxidrome with symptoms of weakness caused by some lignicolous "wood-loving" Psilocybe mushrooms. - Beck SA; Barlow C; Engel L; Barratt MJ. (2025)

Psilocybin With Intracranial Neural Sensing - Joshua Woolley; MD; PhD (ClinicalTrials.gov, 2025)

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach - Jylkkä J. (PsyArXiv, 2025)

Human neuroimaging: fMRI. - Wall MB; Carhart-Harris RL. (2025)

Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives. - Czopek A; Jończyk J; Fryc M; Kluzik D; Zagórska A. (2025)

Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: A qualitative-quantitative approach (PsyArXiv, 2025)

Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study - Matthew Hicks (ClinicalTrials.gov, 2025)

Optimizing Microdosing and Meditation - National University of Natural Medicine (ClinicalTrials.gov, 2025)

Psilocybin’s acute and persistent brain effects: a precision imaging drug trial - Subha Subramanian; Travis Rick Reneau; Demetrius Perry; Ravi V. Chacko; Timothy O. Laumann; Karin Flavin; Christine Horan; Julia Schweiger; Nicholas V. Metcalf; Eric J. Lenze; Abraham Z. Snyder; Nico U.F. Dosenbach; et al. (Scientific Data, 2025)

Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View. - Lashgari NA; Khalaji M; Rana P; Badrabadi F; Rahnama M; Nasoori H; Momeni Roudsari N; Khosravi Nia MM; Shafaroodi H. (2025)

Towards "unmakable" psychedelics: SAR exploration of psilocin analogs obtained by a HATU-mediated amide coupling strategy - Judith Stirn; Raphael Berger; Harald Hübner; Peter Gmeiner; Christian D. Klein (European Journal of Medicinal Chemistry Reports, 2025)

Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms - Abigail M. Blanton; Pooja Parikh; Scott Zhou; Mohamed Mohamed; Rafael Ufret-Vincenty; Ronald Mancini (American Journal of Ophthalmology Case Reports, 2025)

In vitro assessment of psilocin for CYP-dependent drug-drug interaction potential using rapid luminescent assays - Cali James (Drug Metabolism and Pharmacokinetics, 2025)

Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. - Kolasa M; Nikiforuk A; Korlatowicz A; Solich J; Potasiewicz A; Dziedzicka-Wasylewska M; Bugno R; Hogendorf A; Bojarski A; Faron-Górecka A (Psychopharmacology, 2025)

The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies. - Weleff J; Pulido-Saavedra A; Aghaei AM; Ing K; Arakelian M; Fontenele R; Nero N; Barnett BS; Anand A; Bassir Nia A; Angarita GA (Psychiatry research, 2025)

Innovation and inequity in psychedelic research at the Mayo Clinic. - Klim C; VanDreese B; Meyerhoefer T; Breitinger S (History of psychiatry, 2025)

There's More Than One Way to Bring Health Back: Divergent Effects of Psilocybin and Escitalopram Treatment on Emotional Brain Function in Depression. - Fonzo GA; Doss MK; Nemeroff CB. (2025)

Mystical States & Psilocybin. From Dissociation Towards Association: A Conversational Model Discussion - Toby A. Clark (The Therapeutic Conversation, 2025)

Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans. - Berkovitch L; Fauvel B; Preller KH; Gaillard R. (2025)

Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin - Joseph K; Collins J; Genovese T; Maxwell M; Lieberman JA; Osten P. (bioRxiv, 2025)

Publisher’s Note re: “Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions” (doi: 10.1089/psymed.2023.0044) (Psychedelic Medicine, 2025)

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) - Yale University (ClinicalTrials.gov, 2025)

Understanding the Psychological Effects of Psilocybin and 3,4-Methylenedioxymethamphetamine in a Non-Clinical Population - Fitzgerald PB; Webb SL; Denning NC; Dowie T; Schweickle MM; Modak A; Chan G; Knight J; Waldron M; Gainsford K; Hawkes H; Zammit S; et al. (medRxiv, 2025)

Patients’ Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment - Araam Abboud; Clay M. Schiebrel; Ramzi W. Nahhas; Sam Durkin; Kyle Hua; Hannah Redding; Danielle Gainer (Journal of Psychoactive Drugs, 2025)

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study) - University Hospital; Basel; Switzerland (ClinicalTrials.gov, 2025)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium. - Vella Y; Syrová K; Petrušková A; Koutrouli I; Kútna V; Pala J; Šíchová K; Nikolič M; Mazoch V; Jurok R; Kuchař M; Bendová Z; et al. (2025)

Pharmacologic interventions for alcohol use disorder. - Menge J; Evitt B. (2025)

Psilocybin and psilocin regulate microglial immunomodulation and support neuroplasticity via serotonergic and AhR signaling - Salma Laabi; Claire LeMmon; Callie Vogel; M. Chacón; Víctor M. Jiménez (International Immunopharmacology, 2025)

Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa - Stéphanie Knatz Peck; Timothy D. Brewerton; Hannah M. Fisher; Julie Trim; Samantha Shao; Nadav Liam Modlin; Jessie Kim; Daphna M. Finn; Walter H. Kaye (Journal of Eating Disorders, 2025)

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review. - Palmer C; Ferber AT; Greenwald BD. (2025)

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study - Johns Hopkins University (ClinicalTrials.gov, 2025)

Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice - Ines Erkizia-Santamaría; Nerea Martínez-Álvarez; Leyre Salinas-Novoa; J. Javier Meana; Jorge E. Ortega (The International Journal of Neuropsychopharmacology, 2025)

An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) - Charles Raison (ClinicalTrials.gov, 2025)

Clinical pharmacology. - Vogt SB; Liechti ME. (2025)

Age and cannabis co-use moderate experience and perceived benefits of psilocybin - Hooper J; Williams S; Mueller R; Hutchison K. (PsyArXiv, 2025)

Age and cannabis co-use moderate experience and perceived benefits of psilocybin (PsyArXiv, 2025)

Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov. - Swieczkowski D; Kwaśny A; Sadko K; Pruc M; Gaca Z; Szarpak L; Cubała WJ. (2025)

We need to talk about shrooms. - Hellman M (Nordisk alkohol- & narkotikatidskrift: NAT, 2025)

Separate or inseparable? Serotonin and dopamine system interactions may underlie the therapeutic potential of psilocybin for anorexia nervosa. - McCoy K; Reed F; Conn K; Foldi CJ. (2025)

Can the gut-brain axis provide insight into psilocybin's therapeutic value in reducing stress? - Kit A; Conway K; Makarowski S; O'Regan G; Allen J; Shultz SR; Bodnar TS; Christie BR. (2025)

Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments - Basedow LA; Lottes L; Falkenberg I; Vogelbacher C; Yildiz C. (PsyArXiv, 2025)

Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot Phase - University of Wisconsin; Madison (ClinicalTrials.gov, 2025)

Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments (PsyArXiv, 2025)

Psychedelic-like effects induced by 2,5-dimethoxy-4-iodoamphetamine, lysergic acid diethylamide, and psilocybin in male and female C57BL/6J mice - Shelby A. McGriff; Jacquelin C Hecker; Alexander D. Maitland; John S. Partilla; Michael H. Baumann; Grant C. Glatfelter (Psychopharmacology, 2025)

Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions - Roland R. Griffiths; Robert L. Jesse; William A. Richards; Matthew W. Johnson; Nathan D. Sepeda; Anthony P. Bossis; Stephen Ross (Psychedelic Medicine, 2025)

Music and non-music approaches in psilocybin-assisted psychotherapy: The sound of silence - Sara G. Gloeckler; Julien Thibault Lévesque; Alexandre Lehmann; Houman Farzin; Kyle T. Greenway (Journal of Psychedelic Studies, 2025)

Pathway engineering for the biosynthesis of psychedelics. - Abrahms ZN; Sen AK; Jones JA. (2025)

Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder - Icahn School of Medicine at Mount Sinai (ClinicalTrials.gov, 2025)

Serotonergic psychedelics for depression: A comprehensive overview. - Wingert AM; Agnorelli C; Peill J; Reed S; Nutt DJ; Erritzoe D. (2025)

The pharmacological treatment of anxiety in people with eating disorders: A systematic review. - Morris R; Keeler J; Treasure J; Himmerich H. (2025)

Psilocybin and Obsessive-Compulsive Disorder: Exploring New Therapeutic Horizons - Longwei Yang; Haohong Li; Xiaohui Wang (Neuroscience Bulletin, 2025)

A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder - Queen's University (ClinicalTrials.gov, 2025)

Psilocybin-induced modulation of visual salience processing - Muller S; Cavanna F; de la Fuente LA; Bruno N; D’Amelio TA; Pallavicini C; Tagliazucchi E. (bioRxiv, 2025)

Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review. - Estric C; Duron T; Kabani S; Lopez-Castroman J. (2025)

The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field. - Syed OA; Petranker R; Tsang B. (2025)

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review. - Chen MJQ; Chen-Li D; Chisamore N; Husain MI; Di Vincenzo JD; Mansur RB; Phan L; Johnson D; McIntyre RS; Rosenblat JD. (2025)

Exploring the Role of Psychedelics in Modulating Ego and Treating Neuropsychiatric Disorders. - Wang H; Wang X (ACS chemical neuroscience, 2025)

Race/ethnicity moderates the associations between lifetime psilocybin use and opioid use disorder - Grant Jones (PLoS ONE, 2025)

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder - Sharmin Ghaznavi (ClinicalTrials.gov, 2025)

Psilocybin Mitigates Behavioral Despair and Cognitive Impairment in Treatment-resistant Depression Model using Wistar Kyoto Rats - Wang Z; Robbins B; Zhuang R; Bruggen Rv; Sandini T; Li X; Zhang Y. (Research Square, 2025)

A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life. - Kratina S; Strike C; Schwartz R; Nayfeh A; Jopling S; Lo C; Rush B. (2025)

Clade III Synthases Add Cyclic and Linear Terpenoids to the Psilocybe Metabolome - Nick Zschoche; Sebastian Johannes Schober; Karl Walther; A.R. Chadeayne; Markus Gressler; Stefan Bartram; Sarah E. O’Connor; Dirk Hoffmeister (ChemBioChem, 2025)

Cross-Species Evidence for Psilocin-Induced Visual Distortions: Apparent Motion Is Perceived by Both Humans and Rats. - Vejmola Č; Šíchová K; Syrová K; Janečková L; Koudelka V; Tesař M; Nikolič M; Viktorinová M; Tylš F; Korčák J; Viktorin V; Kelemen E; et al. (2025)

FRI-407 Adding the serotonergic agonist psilocybin to semaglutide as a novel combination therapy to cure MASLD - Martina Colognesi; Daniela Gabbia; Anna Signor; Stefano Comai; Andrea Mattarei; Gianfranco Pasut; Lucia Centofanti; Stefano La Rosa; Giovanna Finzi; Franco Folli; M. Pappagallo; Paolo L. Manfredi; et al. (Journal of Hepatology, 2025)

Psilocybin-gestützte Therapie von Depression, Angst und Suchtstörungen: Neurobiologische Grundlagen und klinische Anwendung - Anna Lasch; Timo Schweikert; Eva Dora; Theresa Kolb; Hanne Lilian Schurig; Andreas Walther (Nervenheilkunde, 2025)

Clinical treatment of cluster headache with the serotonergic indoleamine psychedelics psilocybin and LSD and with ketamine: A case series - Jonathan A. Leighton; Carmen Lau; Aisha Savdo; L Granata (Cephalalgia Reports, 2025)

Pharmacokinetics (PK) of psilocybin and psilocin in plasma following intravenous administration of psilocin and oral administration of psilocybin to male beagle dogs - Inés de Lannoy; Lilia Magomedova; Julia Izhakova; Christina de Rivera; James Lanthier; Jason Atkinson; Guy A. Higgins; Malik Slassi; Joseph A. Araujo (Journal of Pharmacological and Toxicological Methods, 2025)

The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Bezo A; Piolino P; Benyamina A (Neuroscience and biobehavioral reviews, 2025)

Divergent Effects of Psilocybin for 2 Patients Participating in a Psilocybin-assisted Cognitive Behavioral Therapy Trial for Major Depressive Disorder. - Weintraub MJ; Miklowitz DJ; Jeffrey JK. (2025)

From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs. - Acero VP; Flatt TA; Gooch PM; Gaughan SJ; Levin AW; Davis AK (Expert review of clinical pharmacology, 2025)

Psilocybin Mushrooms: Identifying the Profile of the Most Likely Users - Gale Wohlfarth (DigitalCommons - Kennesaw State University (Kennesaw State University), 2025)

Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi Study - Kim Hoffman; Todd P. Korthuis; Kellie Pertl; David Morgan (International Journal of Multiple Research Approaches, 2025)

Psilocybin-assisted therapy shows range of benefits in cancer patients (The Brown University Psychopharmacology Update, 2025)

Trial finds psilocybin improves symptoms in treatment-resistant depression (The Brown University Psychopharmacology Update, 2025)

Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom - Wang Y; Li T; Reynolds E; Wang Z; Torrens-Spence M; Weng J. (Research Square, 2025)

University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis - Shayla Frinton; Jill O. Robinson (Journal of Drug Issues, 2025)

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises - Rebecca Harding; Neomi Singer; Matthew B. Wall; Talma Hendler; David Erritzøe; David Nutt; Robin Carhart-Harris; Leor Roseman (Molecular Psychiatry, 2025)

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2025)

Exploring Factors Affecting Psychological Flexibility After Psychedelic Experiences. - Romeo B; Kervadec E; Fauvel B; Strika-Bruneau L; Amirouche A; Verroust V; Piolino P; Benyamina A (Journal of psychoactive drugs, 2025)

The phenomenology of psilocybin: transformative insights for research and clinical practice - Antonio Metastasio; Elisabeth Prevete; Sofia Venturini; Andrea Garofalo; Beatrice Cecconello; Nicola De Pisapia; Ornella Corazza (Frontiers in Psychology, 2025)

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis - Damian Świeczkowski; Aleksander Kwaśny; Michał Pruc; Zuzanna Gaca; Łukasz Szarpak; Wiesław Jerzy Cubała (The International Journal of Psychiatry in Medicine, 2025)

Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis - Jérémie Richard; Jeremy Scott; Sandeep M. Nayak; Nathan D. Sepeda; Matthew X. Lowe; Heather Jackson; Albert Garcia-Romeu (International Journal of Mental Health and Addiction, 2025)

Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics. - Williams ML; Rudin D; Schmid Y; von Salm J. (2025)

5-HT2A receptors: Pharmacology and functional selectivity. - Cummins BR; Billac GB; Nichols DE; Nichols CD. (2025)

Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. - Borgogna NC; Owen T; Petrovitch D; Vaughn J; Johnson DAL; Pagano LA; Aita SL; Hill BD. (2025)

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol - Butler M; Bird C; Maggio C; Durden A; Modlin N; Campbell-Coker K; Edwards M; Pick S; Millman LM; Lowery E; Bhagavan C; Kanaan R; et al. (Wellcome Open Res, 2025)

Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. - Lapid MI; Pagali SR; Randall AL; Donovan KA; Bronars CA; Gauthier TA; Bock J; Lim SD; Carey EC; Sokolowski E; Ulrich AM; Hassett LC; et al. (2025)

Comprehensive analysis of 42 psilocybin-producing fungal strains reveals metabolite diversity and species-specific clusters - Jonathan Cohen; Liron Sulimani; Shiri Procaccia; Yaniv Lerenthal; Looz Milay; Ido Taran; Anna Shapira; David Meiri (Scientific Reports, 2025)

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. - Falchi-Carvalho M; Palhano-Fontes F; Wießner I; Barros H; Bolcont R; Laborde S; Ruschi B Silva S; Montanini D; C Barbosa D; Teixeira E; Florence-Vilela R; Almeida R; et al. (2025)

Effects of psychedelics on human oscillatory brain activity. - Godfrey K; Luan LX; Timmermann C. (2025)

Psychedelics and substance use disorder treatment. - DuPont CM; Johnson MW. (2025)

Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans - Nilubon Thaoboonruang; Ornrat Lohitnavy; Kimheang Ya; Manupat Lohitnavy (Scientific Reports, 2025)